Recurrent GI infection
When protective communities are depleted, opportunistic pathogens recur. Restoring colonization resistance offers an alternative to repeated antibiotic cycles.
Learn more →
Restoring the gut ecosystem to prevent disease
GutRecover Therapeutics is advancing microbiome-based therapies that rebuild healthy gut ecology — addressing the underlying drivers of gastrointestinal and immune-mediated disease.
Upcoming: GutRecover at IDWeek 2027 — advancing GR-101 (RESTORe-101, recurrent C. difficile infection).
Learn more
Commitment to patients
Treating the ecosystem, not only the symptom
Gut dysbiosis is a known driver of gastrointestinal disease. Our therapies are designed to re-establish protective microbial communities and the responses they coordinate — offering durable alternatives to symptom-only treatment.
Defined consortia
Therapies built as defined communities of well-characterized strains — selected for complementary function, stability, and safety, not sourced from donors.
Learn more →Clinical development
A focused, staged program advancing our lead candidates through rigorous evaluation of efficacy and safety in target indications.
Learn more →
Our science
From ecological insight to defined, manufacturable therapies
A disciplined, three-stage approach that turns gut ecology into reproducible medicine.
Map the disrupted ecosystem
We characterize how microbial communities differ between health and disease, identifying the ecological functions that are lost — and the organisms that restore them.
Learn more →Compose defined consortia
Candidate therapies are built as defined communities of well-characterized strains — selected for complementary function, stability, and safety.
Learn more →Manufacture with consistency
Each consortium is produced under controlled, scalable processes — giving clinicians and regulators the consistency expected of a modern pharmaceutical product.
Learn more →
The science behind our approach
Restore the function, and the gut defends itself
Antibiotics and infection strip out the bacteria that produce secondary bile acids and short-chain fatty acids — the metabolites that keep pathogens out and the immune system calm. Our consortia are designed to put those functions back.
- Resistance Secondary bile acids made by gut commensals directly suppress C. difficile. Deplete the bacteria, and colonization resistance collapses.
- Immunity Microbial short-chain fatty acids induce regulatory T cells that hold intestinal inflammation in check.
- Defined Characterized consortia reproduce these effects without the variability of donor-derived material — and have demonstrated it in controlled clinical studies.
// Foundational evidence
Precision microbiome reconstitution restores bile-acid-mediated resistance to C. difficile.
Buffie et al. — the mechanistic keystone: defined organisms, not whole stool, restore the metabolites that block infection.
Treg induction by a rationally selected mixture of Clostridia strains.
Atarashi et al. — proof that a deliberately composed, defined consortium can reprogram the gut immune response.
VE303, a defined bacterial consortium, for prevention of recurrent C. difficile infection.
Louie et al. — the modality translating: a defined, donor-free consortium reducing recurrence in a controlled human trial.
Pipeline & programs
Three programs. One platform. A defined path to the clinic.
Explore our pipeline →
Programs
A focused, staged development program
ProgramIndication
DiscoveryPreclinicalPhase 1Phase 2
GR-101Lead program
Recurrent C. difficile infection (rCDI)
GR-201
Ulcerative colitis
GR-301
Gut–immune axis (undisclosed)
Why this matters
Recurrent gut infection is a treatable failure of ecology
When the protective community collapses, the same infection returns again and again. Restoring the ecosystem — reproducibly, with defined consortia — is how we intend to break the cycle.
See the programs →
Who we are
A team that takes the science seriously
Experience across microbiology, clinical development, manufacturing, and company building — united by the conviction that the gut ecosystem is the next frontier of therapeutic development.
Meet the team →
Partnerships
Partnering to translate gut ecology into medicine
We work with pharmaceutical companies, academic groups, and investors who share our conviction that the gut ecosystem is the next frontier of therapeutic development.
Start a conversation →